PROTAC CYP1B1 degrader-2

PROTAC CYP1B1 degrader-2 (Compound PV2) (0.1-10000 nM; 1-48 h) potently induces proteasomal degradation of CYP1B1 in A549/Taxol cells, with a DC₅₀ of approximately 0.1 nM; it achieves >90% degradation at a concentration of 10 nM, and nearly complete degradation within 24 h at 10 nM^[1].
PROTAC CYP1B1 degrader-2 (0.1-10 nM; 48 h) enhances the sensitivity of A549/Taxol cells to Taxol in a concentration-dependent manner, effectively reverses Taxol resistance, and exhibits stronger potency than the CYP1B1 inhibitor A1^[1].
PROTAC CYP1B1 degrader-2 (0.1-10 nM; 48 h) inhibits the migration of A549/Taxol cells in a concentration-dependent manner, with significant effects at concentrations of 1 nM and 10 nM^[1].
PROTAC CYP1B1 degrader-2 (0.1-10 nM) inhibits the invasion of A549/Taxol cells, with a significant effect observed at 10 nM^[1].
PROTAC CYP1B1 degrader-2 (0.1-10 nM; 3 h) inhibits the efflux function of P-gp in A549/Taxol cells and increases the intracellular accumulation of Rho123^[1].
PROTAC CYP1B1 degrader-2 (0.1-10 nM; 24 h) downregulates the FAK/SRC-paxillin pathway in A549/Taxol cells, and inhibits FAK phosphorylation, SRC activity and expression, as well as paxillin expression^[1].
PROTAC CYP1B1 degrader-2 (0.1-10 nM; 24 h) inhibits the EMT pathway in A549/Taxol cells by upregulating E-cadherin and downregulating N-cadherin and vimentin^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.